Number of eligible individuals: CDEC talked about the uncertainty in the amount of individuals with moderately serious to serious hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some people that are labeled as obtaining gen